OS Therapies Incorporated (OSTX)

OS Therapies Incorporated is a clinical-stage biopharmaceutical company focused on treatments for osteosarcoma, a bone cancer that mainly affects children and young adults, and other solid tumors.

Its lead candidate, OST-HER2, is an immunotherapy built on an attenuated Listeria monocytogenes bacterium engineered to deliver a HER2 antigen, training the immune system to attack HER2-expressing cancer cells. The company has studied OST-HER2 in patients with recurrent, fully resected pulmonary metastatic osteosarcoma with the aim of preventing further recurrence.

The company is also developing antibody-drug conjugate technology for targeted delivery of cancer-killing payloads. Its common stock trades on NYSE American.